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Abstract
AIM: To investigate the pathogenesis of non-alcoholic 
fatty liver disease (NAFLD) after pancreatoduodenec-
tomy (PD). 
METHODS: A cohort of 82 patients who underwent 
PD at Okayama University Hospital between 2003 and 
2009 was enrolled and the clinicopathological features 
were compared between patients with and without 
NAFLD after PD. Computed tomography (CT) images 
were evaluated every 6 mo after PD for follow-up. He-
patic steatosis was diagnosed on CT when hepatic at-
tenuation values were 40 Hounsfield units. Liver biopsy 
was performed for 4 of 30 patients with NAFLD after 
PD who consented to undergo biopsies. To compare 
NAFLD after PD with NAFLD associated with metabolic 
syndrome, liver samples were obtained from 10 pa-
tients with NAFLD associated with metabolic syndrome 
[fatty liver, n  = 5; non-alcoholic steatohepatitis (NASH), 
n  = 5] by percutaneous ultrasonography-guided liver 
biopsy. Double-fluorescence immunohistochemistry 
was applied to examine CD14 expression as a marker 
of lipopolysaccharide (LPS)-sensitized macrophage 
cells (Kupffer cells) in liver biopsy specimens.
RESULTS: The incidence of postoperative NAFLD was 
36.6% (30/82). Univariate analysis identified cancer of 
the pancreatic head, sex, diameter of the main pancre-
atic duct, and dissection of the nerve plexus as factors 
associated with the development of NAFLD after PD. 
Those patients who developed NAFLD after PD demon-
strated significantly decreased levels of serum albumin, 
total protein, cholesterol and triglycerides compared to 
patients without NAFLD after PD, but no glucose intol-
erance or insulin resistance. Liver biopsy was performed 
in four patients with NAFLD after PD. All four patients 
showed moderate-to-severe steatosis and NASH was 
diagnosed in two. Numbers of cells positive for CD68 
(a marker of Kupffer cells) and CD14 (a marker of LPS-
sensitized Kupffer cells) were counted in all biopsy 
specimens. The number of CD68+ cells in specimens 
of NAFLD after PD was significantly increased from 
that in specimens of NAFLD associated with metabolic 
syndrome specimens, which indicated the presence of 
significantly more Kupffer cells in NAFLD after PD than 
in NAFLD associated with metabolic syndrome. Simi-
larly, more CD14+ cells, namely, LPS-sensitized Kupffer 
cells, were observed in NAFLD after PD than in NAFLD 
associated with metabolic syndrome. Regarding NASH, 
more CD68+ cells and CD14+ cells were observed in 
NASH after PD specimens than in NASH associated with 
metabolic syndrome. This showed that more Kupffer 
cells and more LPS-sensitized Kupffer cells were pres-
ent in NASH after PD than in NASH associated with 
metabolic syndrome. These observations suggest that 
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after PD, Kupffer cells and LPS-sensitized Kupffer cells 
were significantly upregulated, not only in NASH, but 
also in simple fatty liver.
CONCLUSION: NAFLD after PD is characterized by 
both malnutrition and the up-regulation of CD14 on 
Kupffer cells. Gut-derived endotoxin appears central to 
the development of NAFLD after PD.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
The prevalence of  non-alcoholic fatty liver disease 
(NAFLD) associated with metabolic syndrome is increas-
ing worldwide[1,2]. NAFLD associated with metabolic 
syndrome is considered to be associated with chronic 
over-nutrition that results in the accumulation of  visceral 
fat and obesity and is one of  the most common forms 
of  chronic liver disease[3]. NAFLD associated with meta-
bolic syndrome is related to states such as severe obesity, 
impairment of  glucose tolerance and hyperlipidemia[4]. 
Indeed, several studies have shown strong relationships 
among NAFLD associated with metabolic syndrome, he-
patic insulin resistance and type 2 diabetes mellitus[5-7].
On the other hand, NAFLD sometimes develops 
after pancreatoduodenectomy (PD)[8]. Tanaka et al[9] re-
cently reported that NAFLD after PD was characterized 
by non-obesity and a lack of  both hyperlipidemia and 
insulin resistance. The pathogenesis of  NAFLD after PD 
may thus differ from the pathogenesis of  NAFLD asso-
ciated with metabolic syndrome.
Recently, Tilg et al[10] proposed a new model, suggest-
ing that many hits may act in parallel to finally result in 
liver inflammation, with gut and adipose tissue-derived 
factors in particular playing a central role. It was reported 
that the clinical features of  the patients with NAFLD 
after PD are similar to those found in the murine non-
alcoholic steatohepatitis (NASH) model induced by a 
methionine-choline-deficient (MCD) diet[9]. In mice fed 
the MCD diet, portal endotoxemia due to an impaired 
gut barrier caused by the MCD diet was observed[11]. We 
therefore hypothesized that gut-derived lipopolysaccha-
ride (LPS) was associated with NAFLD after PD. LPS 
might trigger the release of  inflammatory cytokines from 
Kupffer cells, in turn mediating severe hepatic steatosis 
and liver injury after PD. The process by which LPS acti-
vates Kupffer cells seems to be mediated by LPS-binding 
protein, CD14 and toll-like receptor 4[12]. We therefore 
focused on the CD14 expression on Kupffer cells from 
liver specimens in cases of  NAFLD after PD.
We examined the prevalence, clinical and histological 
features, and expression of  CD14 as a marker of  LPS-
sensitized Kupffer cells in liver tissues obtained from 
patients with either NAFLD associated with metabolic 
syndrome or NAFLD after PD.
MATERIALS AND METHODS
Between February 2003 and August 2009, a total of  100 
patients underwent PD at Okayama University Hospital, 
Okayama, Japan. Of  these, 18 patients were excluded 
from the study because they were unavailable for regular 
follow-up computed tomography (CT) of  the abdo-
men. The remaining 82 patients (49 men and 33 women) 
were enrolled in this study. There were no patients with 
preoperative NAFLD, based on CT and laboratory find-
ings. The mean age at the time of  surgery was 63 years 
(range 31-85 years). Histological diagnosis was pancreatic 
carcinoma in 32 patients, intraductal papillary-mucinous 
neoplasm in 27, bile duct carcinoma in 3, and others in 
20. In terms of  surgical procedures, conventional PD 
was employed for 73 patients and pylorus-preserving PD 
for 9 patients. For patients with adenocarcinoma of  the 
pancreatic head, we routinely performed dissection of  
the nerve plexus around the superior mesenteric artery 
(SMA), leaving the left side of  the SMA near the origin 
intact. A modification of  Child’s method was employed 
for digestive reconstruction.
Body mass index (BMI) was determined for all pa-
tients and blood examinations were performed before 
and every 3 mo after PD. Follow-up continued for more 
than 12 mo in all cases. Routine blood examinations in-
cluded fasting lipid, blood glucose and insulin levels, and 
levels of  hemoglobin (HbA1c), asparate aminotransferase 
(AST), alanine aminotransferase, total protein, albumin 
and cholinesterase.
CT images were obtained using a 16-multidetector 
CT scanner (GE Yokogawa, Tokyo, Japan) without in-
travenous contrast medium. The raw data set was recon-
structed at 5 mm thickness. CT images were evaluated 
every 6 mo after PD for follow-up. Hepatic steatosis was 
diagnosed on CT when hepatic attenuation values were 
40 Hounsfield units. According to this criterion, 30 of  82 
patients who underwent PD were found to have newly 
appearing hepatic steatosis.
Liver biopsy was performed for 4 of  30 patients with 
NAFLD after PD who consented to undergo biopsies 
(fatty liver, n = 2; NASH, n = 2); in these two men and 
two women, the mean age was 61 (52-73) years, histologi-
cal diagnosis was pancreatic carcinoma in one patient, in-
traductal papillary-mucinous neoplasm in two, and serous 
cyst adenoma in one, and all of  them underwent PD. To 
compare NAFLD after PD with NAFLD associated with 
metabolic syndrome, liver samples were obtained from 
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10 patients with NAFLD associated with metabolic syn-
drome (fatty liver, n = 5; NASH, n = 5) by percutaneous 
ultrasonography-guided liver biopsy; these four men and 
six women had a mean age of  52 (40-64) years. In 10 pa-
tients, NAFLD associated with metabolic syndrome was 
diagnosed by the following criteria: (1) the absence of  
regular intake of  alcohol and past history of  abdominal 
surgery; (2) negative results for hepatitis B virus surface 
antigen and anti-hepatitis C virus antibodies; and (3) the 
absence of  other types of  chronic liver disease.
Specimens were fixed in 40 g/L neutral-buffered 
formaldehyde, cut at 4 µm thickness and stained using 
hematoxylin and eosin or the Azan-Mallory method. His-
tological findings were assessed in a blinded fashion by an 
independent pathologist. Histological diagnosis of  NASH 
was made based on the presence of  macrovesicular ste-
atosis, hepatocyte ballooning and lobular inflammation.
For double immunofluorescence, tissue array slides 
were deparaffinized and soaked in 0.01 mol/L citrate buf-
fer (pH 6.0) at 90 ℃ for 30 min for antigen retrieval. Sam-
ples were treated with 10 mg/mL bovine serum albumin 
(BSA) to inhibit non-specific antibody binding, then incu-
bated with primary murine monoclonal antibody to CD68 
(Kp-1, dilution 1:500; Dako, Glostrup, Denmark) for 1 
h at 37 ℃. After washing three times with phosphate-
buffered saline (PBS) (pH 7.2), samples were incubated 
with Cy5-labeled secondary rabbit polyclonal antibody to 
murine immunoglobulin G for 30 min at 37 ℃. For the 
second immunoreaction, a similar procedure was used: 
samples were treated with 10 mg/mL BSA, then incubat-
ed with another primary antibody to CD14 (dilution 1:100; 
Zymed Laboratories, San Francisco, CA), then incubated 
with fluoresceinisothiocyanate isomer (FITC)-labeled sec-
ondary antibody. After washing with PBS, Cy5-labeled and 
FITC-labeled samples were examined using a fluorescence 
microscope (SZX12; Olympus, Tokyo, Japan).
Frequencies of  double-positive cells were determined 
by histology experts counting these cells in entire speci-
mens. Double-positive cells in the hepatic lobule were 
counted in five high-power fields (original magnification 
×60). Cell counts are expressed as the mean ± SD in each 
specimen.
Statistical analysis
Statistical analysis were performed using SPSS for Win-
dows version 11.0 software (SPSS, Chicago, IL, United 
States). Continuous variables are expressed as mean ± SD 
and the statistical significance of  differences was deter-
mined using Student’s t test. Comparisons between groups 
were made using the χ 2 test for categorical variables. Val-
ues of  P < 0.05 were considered statistically significant.
RESULTS
The median follow-up for the 82 patients who under-
went PD was 840 d (range, 183-2553 d). The frequency 
of  NAFLD after PD was 36.6% (30/80). Clinical pre- 
and intraoperative data for patients with NAFLD (n = 
30, 36.6%) and patients without NAFLD (n = 52, 63.4%) 
are summarized in Table 1. Univariate analysis identi-
fied cancer of  the pancreatic head, sex, diameter of  the 
main pancreatic duct (MPD) and dissection of  the nerve 
plexus as factors associated with the development of  
NAFLD after PD.
Clinical postoperative data for patients with and with-
out NAFLD are summarized in Table 2. The BMI, serum 
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Non-NAFLD NAFLD P value1 
(n  = 52) (n  = 30)
  BMI (kg/m2)     21.7 ± 3.3   21.4 ± 2.6    0.622
  Age (yr)     63.6 ± 10.9   63.4 ± 11.9    0.940
  Pancreatic head cancer (yes)     31%   53% < 0.0012
  Sex (male)     69%   43%    0.0352
  Diameter of MPD (mm)       3.9 ± 3.2     5.6 ± 3.2    0.025
  Total cholesterol (mg/dL)3   188.2 ± 53.3 202.0 ± 39.9    0.238
  Triglycerides (mg/dL)3   119.8 ± 69.2 139.9 ± 74.8    0.363
  Total protein (g/dL)3       8.0 ± 0.9     8.3 ± 0.5    0.322
  Albumin (g/dL)3       4.0 ± 0.4     4.0 ± 0.5    0.761
  Cholinesterase (U/L)3   230.6 ± 88.2 244.5 ± 104.9    0.531
  Insulin (µU/mL)3       5.5 ± 2.3     7.7 ± 3.5    0.500
  HOMA-IR3       1.6 ± 1.0     3.2 ± 3.4    0.324
  HbA1c (%)3       5.5 ± 0.8     6.2 ± 1.8    0.060
  ALT3     65.6 ± 0.8   79.9 ± 107.3    0.506
  Operation (PPPD)     15%   10%    0.7382
  Operation time (min)   400.9 ± 49.0 394.6 ± 37.8    0.544
  Intraoperative blood loss (mL)   425.2 ± 171.9 419.3 ± 155.6    0.878
  Patients with nerve plexus 
  dissection
    15%   93% < 0.0012
  Pancreatic resection line (SMA)     19%   37%    0.0812
Table 1 Comparison between pre- and intra-operative data 
between patients with and without non-alcoholic fatty liver 
disease after pancreatoduodenectomy
1P values calculated using the χ 2 test; 2P values calculated using Fisher’s 
exact test; 3Values represent mean ± SD unless otherwise indicated. NAFLD: 
Non-alcoholic fatty liver disease; BMI: Body mass index; MPD: Main pancre-
atic duct; HOMA-IR: Homeostasis model assessment for insulin resistance; 
HbA1c: Hemoglobin A1c; ALT: Alanine aminotransferase; PPPD: Pylorus 
preserving pancreaticoduodenectomy; SMA: Superior mesenteric artery. 
Non-NAFLD NAFLD P value1 
(n  = 52) (n  = 30)
  BMI (kg/m2)2      20.1 ± 3.5     17.4 ± 2.8     0.004
  Total cholesterol (mg/dL)2    159.2 ± 40.4   133.3 ± 36.4     0.011
  Triglycerides (mg/dL)2    102.2 ± 36.4     84.9 ± 49.0     0.169
  Total protein (g/dL)2        7.0 ± 0.7       6.1 ± 0.7 < 0.001
  Albumin (g/dL)2        4.0 ± 0.5       3.1 ± 0.7 < 0.001
  Cholinesterase (U/L)2    215.5 ± 78.5   156.9 ± 88.1     0.006
  Insulin (µU/mL)2        9.7 ± 9.8       4.1 ± 3.8     0.009
  HOMA-IR2        3.1 ± 3.3       1.3 ± 1.2     0.117
  HbA1c (%)2        5.5 ± 0.9       5.6 ± 0.9     0.589
  ALT2      31.6 ± 18.5     52.0 ± 45.1     0.033
  Insulin treatment      12%     27%     0.126
Table 2  Comparison of postoperative data between patients 
with and without non-alcoholic fatty liver disease after pan-
creatoduodenectomy
1P values calculated using the χ 2 test; 2Measured 6 mo postoperatively. 
Values represent mean ± SD unless otherwise indicated. NAFLD: Non-al-
coholic fatty liver disease; BMI: Body mass index; HOMA-IR: Homeostasis 
model assessment for insulin resistance; HbA1c: Hemoglobin A1c; ALT: 
Alanine aminotransferase. 
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Numbers of  cells positive for CD68 (a marker of  
Kupffer cells) and CD14 (a marker of  LPS-sensitized 
Kupffer cells) were counted in all biopsy specimens (Figure 
1). The mean number of  CD68+ cells per individual was 
50.6 ± 4.0 in specimens from NAFLD associated with 
metabolic syndrome and 104.3 ± 13.3 in specimens from 
NAFLD after PD, indicating the presence of  significantly 
more Kupffer cells in NAFLD after PD than in NAFLD 
associated with metabolic syndrome (P < 0.001) (Figure 2). 
CD14+ cells were observed in specimens from NAFLD 
associated with metabolic syndrome and in specimens from 
NAFLD after PD, with mean positive cell counts of  0.6 ± 
0.3 and 13.5 ± 4.2, respectively, showing more LPS-sensi-
tized Kupffer cells in NAFLD after PD than in NAFLD 
associated with metabolic syndrome (P < 0.001) (Figure 
2). We also attempted to classify NAFLD into simple fatty 
liver or NASH. As for simple fatty liver, mean numbers 
of  CD68+ cells and CD14+ cells per individual were 51.0 
± 6.8 and 0.4 ± 0.2, respectively, in specimens from fatty 
liver associated with metabolic syndrome and 116.0 ± 10.7 
and 20.5 ± 2.5, respectively, in specimens from fatty liver 
after PD. This indicated the presence of  more Kupffer 
cells and more LPS-sensitized Kupffer cells in specimens 
from simple fatty liver after PD than in specimens from 
simple fatty liver associated with metabolic syndrome (P < 
0.001, CD68+ cells; P < 0.001, CD14+ cells). Regarding 
NASH, the mean numbers of  CD68+ cells and CD14+ 
cells per individual were 50.2 ± 7.4 and 0.8 ± 0.6, respec-
tively, in specimens from NASH associated with metabolic 
syndrome and 92.5 ± 19.5 and 6.5 ± 0.5, respectively, in 
specimens from NASH after PD. This showed that more 
Kupffer cells and more LPS-sensitized Kupffer cells were 
present in specimens from NASH after PD than in speci-
mens from NASH associated with metabolic syndrome 
(CD68+ cells, P < 0.05; CD14+ cells, P < 0.05) (Figure 3). 
These observations suggest that after PD, Kupffer cells and 
LPS-sensitized Kupffer cells were significantly upregulated, 
not only in NASH, but also in simple fatty liver.
DISCUSSION
Conventional NAFLD is thought to be caused by exces-
levels of  total protein and albumin, and levels of  cholin-
esterase, total cholesterol and insulin were significantly 
lower in patients with NAFLD after PD than in patients 
without NAFLD. Homeostasis model assessment for 
insulin resistance values, as an indicator of  insulin resis-
tance, and serum levels of  triglycerides and HbA1c did 
not differ between these two groups.
At 6 mo postoperatively, 17 of  the 30 patients (57%) 
with NAFLD after PD showed increased blood levels of  
AST. Of  these 17 patients, we performed liver biopsies 
to pathologically examine specimens from four patients 
[mean serum levels of  AST was 67 (54-80) U/L] who 
consented to undergo biopsies. Histopathological exami-
nation diagnosed two cases as stage 2 NASH, according 
to the Brunt criteria[13], and two cases as moderate-to-
severe macrovesicular steatosis.
In the 10 patients with NAFLD associated with meta-
bolic syndrome, the mean serum level of  AST was 56 
(35-112) U/L. Five of  10 patients showed moderate-to-
severe macrovesicular steatosis and the remaining five pa-
tients showed stage 2 NASH in histological examination.
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Figure 1  Immunohistochemical staining of liver biopsy specimens for CD68 and CD14 (×60). Kupffer cells (CD68+) and lipopolysaccharide-sensitized Kupffer 
cells (CD14+) were compared between samples from conventional non-alcoholic fatty liver disease (NAFLD) and NAFLD after pancreatoduodenectomy (PD). Long 
arrows represent CD68+ Kupffer cells; Short arrows represent CD68+ and CD14+ Kupffer cells. A: Conventional NAFLD; B: NAFLD after PD.
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Figure 2  Number of cells positive for CD68 (a marker of Kupffer cells) 
and CD14 (a marker of lipopolysaccharide-sensitized Kupffer cells). Con-
ventional non-alcoholic fatty liver disease (NAFLD) and NAFLD after pancre-
atoduodenectomy (PD). Conventional NAFLD and NAFLD after PD specimens 
showed mean cell counts of 50.6 ± 4.0 and 104.3 ± 13.3 CD68+ Kupffer cells 
per individual, respectively (aP < 0.05). Cell counts for CD14+ Kupffer cells were 
0.6 ± 0.3 and 13.5 ± 4.2 cells per individual, respectively (bP < 0.001).
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sive nutrition, lipid metabolic disorder and insulin resis-
tance, as a part of  metabolic syndrome[4]. However, the 
present study demonstrated that NAFLD after PD was 
related to non-obese status, malnutrition and lack of  hy-
perlipidemia and insulin resistance. These findings suggest 
that the mechanisms underlying NAFLD after PD differ 
from those causing NAFLD associated with metabolic 
syndrome. Recent studies have also suggested that pancre-
atic exocrine insufficiency may cause NAFLD after PD[8,9]. 
Although only univariate analyses were examined in our 
study, pancreatic cancer was associated with the develop-
ment of  NAFLD, which is considered to lead to impaired 
pancreatic exocrine functions due to obstruction of  the 
MPD, in turn resulting in obstructive distal pancreatic at-
rophy and fibrosis.
The clinical features of  patients with NAFLD after 
PD resemble those in mice with MCD-induced NASH, 
in terms of  the absence of  obesity, insulin resistance and 
hypocholesterolemia[14]. Increased fatty acid uptake and 
decreased hepatic export of  triglycerides in the form 
of  very-low-density lipoprotein (VLDL) represent two 
important mechanisms contributing to MCD-induced 
NASH[14,15]. Malabsorption of  essential amino acids such 
as choline due to pancreatic exocrine insufficiency may 
result in the development of  NAFLD after PD.
NAFLD is often observed in patients showing hypo-
insulinemia. Insulin inhibits lipolysis in adipose tissue and 
decreases the flux of  free fatty acids (FFA) into plasma. 
In the absence of  adequate insulin secretion, plasma FFA 
levels could conceivably be elevated due to increased adi-
pose tissue lipolysis and the liver would then be unable to 
adequately couple triglycerides to apoprotein B or secrete 
VLDL-triglyceride, resulting in hepatic steatosis[16]. In 
this study, serum insulin concentrations were significantly 
lower in NAFLD after PD compared with non-NAFLD 
after PD. Insufficiency of  insulin may be another factor 
contributing to the development of  NAFLD after PD.
We performed liver biopsy in four patients with 
NAFLD after PD, diagnosing two cases of  NASH. 
Kupffer cell counts have been shown to play important 
roles in the pathogenesis of  NASH[17]. Within the liver, 
Kupffer cells are major sources of  tumor necrosis factor-
alpha (TNF-a) produced in response to LPS[12,18,19]. The 
process by which LPS activates Kupffer cells seems to 
be mediated by LPS-binding protein, CD14 and toll-like 
receptor 4[20]. We therefore focused on CD14 expression 
in liver specimens from NAFLD after PD because the 
promoter polymorphism of  CD14 has been reported as 
a risk factor for both alcoholic and non-alcoholic steato-
hepatitis[21]. CD14 expression on Kupffer cells is low in 
the healthy human liver[22,23] but increases in the presence 
of  inflammatory liver disease[24]. Expression of  CD14 on 
Kupffer cells can be upregulated with LPS[25,26]. A previ-
ous study reported that TNF-a production was decreased 
in genetically engineered CD14-deficient mice by down-
regulating sensitivity to LPS[27]. In contrast, the CD14 
transgenic mice that overexpress CD14 on monocytes 
showed increased sensitivity to LPS[28]. These changes in 
CD14 expression could represent a mechanism regulating 
liver sensitivity to LPS toxicity.
The present study demonstrated that Kupffer cells 
were significantly more common and LPS-induced 
CD14+ Kupffer cells were upregulated in NAFLD after 
PD specimens compared to NAFLD associated with 
metabolic syndrome specimens. Furthermore, even in 
simple fatty liver after PD specimens, more Kupffer cells 
and more LPS-sensitized Kupffer cells were present than 
in specimens from simple fatty liver associated with met-
abolic syndrome. These findings indicate that LPS plays 
a significant role in the occurrence of  NAFLD after PD, 
even from an early stage.
Previous reports have hypothesized that the over-
growth of  small intestinal bacteria might play a con-
tributory role in NASH pathogenesis, particularly via a 
component of  the gram-negative bacterial population, 
through the production of  LPS[29-33]. Among those pa-
tients who underwent PD, bacterial overgrowth may have 
occurred due to dissection around the SMA, leading to 
intestinal motor dysfunction and stasis, decreased secre-
tion of  gastric juices or blind loops.
The fatty liver is vulnerable to additional inflammato-
ry insults, such as oxidative stress and gut-derived bacte-
rial endotoxins, both of  which can trigger hepatocellular 
inflammation and fibrosis[34,35]. Accumulation of  FFA in 
the liver due to malabsorption of  essential amino acids 
such as choline and gut-derived LPS perhaps from intes-
tinal bacterial overgrowth are important in the pathogen-
esis of  NAFLD after PD.
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Figure 3  Number of cells positive for CD68 (a marker of Kupffer cells) and 
CD14 (a marker of lipopolysaccharide-sensitized Kupffer cells). Conven-
tional fatty liver and fatty liver after pancreatoduodenectomy (PD), in conven-
tional non-alcoholic steatohepatitis (NASH) and in NASH after PD. For simple 
steatosis, mean counts of CD68+ and CD14+ cells were 51.0 ± 6.8 and 0.4 ± 
0.2 cells per individual in conventional fatty liver specimens, respectively, and 
116.0 ± 10.7 and 20.5 ± 2.5 cells per individual, respectively, in fatty liver after 
PD specimens. This indicates more Kupffer cells and more lipopolysaccharide-
sensitized Kupffer cells in simple fatty liver after PD specimens than in conven-
tional simple fatty liver specimens (bP < 0.001; dP < 0.001). Regarding NASH, 
mean cell counts for CD68+ cells and CD14+ cells were 50.2 ± 7.4 and 0.8 ± 0.6 
cells per individual, respectively, in conventional NASH specimens, and 92.5 
± 19.5 and 6.5 ± 0.5 cells per individual, respectively, in NASH after PD speci-
mens. This showed that more Kupffer cells and more LPS-sensitized Kupffer 
cells were present in NASH after PD specimens than in conventional NASH 
specimens (aP < 0.05; cP < 0.05).
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In conclusion, NAFLD after PD is characterized, not 
only by malnutrition, but also by up-regulation of  CD14 
on Kupffer cells with hepatic steatosis. Our results sug-
gest that gut-derived endotoxin contributes to the devel-
opment of  NAFLD after PD.
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